Molecular, serological, and biochemical diagnosis and monitoring of COVID-19: IFCC taskforce evaluation of the latest evidence
- 12 May 2020
- journal article
- review article
- Published by Walter de Gruyter GmbH in cclm
- Vol. 58 (7), 1037-1052
- https://doi.org/10.1515/cclm-2020-0722
Abstract
The global coronavirus disease 2019 (COVID-19) has presented major challenges for clinical laboratories, from initial diagnosis to patient monitoring and treatment. Initial response to this pandemic involved the development, production, and distribution of diagnostic molecular assays at an unprecedented rate, leading to minimal validation requirements and concerns regarding their diagnostic accuracy in clinical settings. In addition to molecular testing, serological assays to detect antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are now becoming available from numerous diagnostic manufacturers. In both cases, the lack of peer-reviewed data and regulatory oversight, combined with general misconceptions regarding their appropriate use, have highlighted the importance of laboratory professionals in robustly validating and evaluating these assays for appropriate clinical use. The International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) Task Force on COVID-19 has been established to synthesize up-to-date information on the epidemiology, pathogenesis, and laboratory diagnosis and monitoring of COVID-19, as well as to develop practical recommendations on the use of molecular, serological, and biochemical tests in disease diagnosis and management. This review summarizes the latest evidence and status of molecular, serological, and biochemical testing in COVID-19 and highlights some key considerations for clinical laboratories operating to support the global fight against this ongoing pandemic. Confidently this consolidated information provides a useful resource to laboratories and a reminder of the laboratory’s critical role as the world battles this unprecedented crisis.Keywords
This publication has 103 references indexed in Scilit:
- Clinical features of patients infected with 2019 novel coronavirus in Wuhan, ChinaThe Lancet, 2020
- Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCREurosurveillance, 2020
- Practical recommendations for managing hemolyzed samples in clinical chemistry testingcclm, 2018
- Epidemiology and outcomes of acute kidney injury in elderly chinese patients: a subgroup analysis from the EACH studyBMC Nephrology, 2016
- Immunoglobulin M for Acute Infection: True or False?Clinical and Vaccine Immunology, 2016
- Prevalence of Antibodies to Four Human Coronaviruses Is Lower in Nasal Secretions than in SerumClinical and Vaccine Immunology, 2010
- Acute renal impairment in coronavirus-associated severe acute respiratory syndromeKidney International, 2005
- Chronological evolution of IgM, IgA, IgG and neutralisation antibodies after infection with SARS-associated coronavirusClinical Microbiology & Infection, 2004
- Profile of Specific Antibodies to the SARS-Associated CoronavirusNew England Journal of Medicine, 2003
- Qualitative dynamics of a network model of regulation of the immune system: A rationale for the IgM to IgG switchJournal of Theoretical Biology, 1982